383 related articles for article (PubMed ID: 25687212)
1. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
2. How the flexibility of human histone deacetylases influences ligand binding: an overview.
Deschamps N; Simões-Pires CA; Carrupt PA; Nurisso A
Drug Discov Today; 2015 Jun; 20(6):736-42. PubMed ID: 25597521
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction.
Silvestri L; Ballante F; Mai A; Marshall GR; Ragno R
J Chem Inf Model; 2012 Aug; 52(8):2215-35. PubMed ID: 22762501
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
5. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
[TBL] [Abstract][Full Text] [Related]
6. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
10. Structural biology of human metal-dependent histone deacetylases.
Schapira M
Handb Exp Pharmacol; 2011; 206():225-40. PubMed ID: 21879452
[TBL] [Abstract][Full Text] [Related]
11. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
12. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
13. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
14. Structure-function analysis of the conserved tyrosine and diverse π-stacking among class I histone deacetylases: a QM (DFT)/MM MD study.
Zhou J; Xie H; Liu Z; Luo HB; Wu R
J Chem Inf Model; 2014 Nov; 54(11):3162-71. PubMed ID: 25360823
[TBL] [Abstract][Full Text] [Related]
15. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
16. Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.
Zhu Y; Li HF; Lu S; Zheng YX; Wu Z; Tang WF; Zhou X; Lu T
Eur J Med Chem; 2010 May; 45(5):1777-91. PubMed ID: 20153566
[TBL] [Abstract][Full Text] [Related]
17. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
[TBL] [Abstract][Full Text] [Related]
18. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
19. Chemical and structural biology of protein lysine deacetylases.
Yoshida M; Kudo N; Kosono S; Ito A
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
Reddy DR; Ballante F; Zhou NJ; Marshall GR
Eur J Med Chem; 2017 Feb; 127():531-553. PubMed ID: 28109947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
